AQ-13对比蒿甲醚-苯芴醇治疗无并发症恶性疟的随机2期非劣效试验
该随机2期非劣效试验在66名马里男性无并发症恶性疟患者中比较AQ-13与蒿甲醚-苯芴醇的疗效。
要点
- 意向性分析因脱落导致AQ-13非劣效未成立,但无治疗失败。
- 两组均无严重不良事件,AQ-13组不良事件略多但均为轻度。
核心结论
- 符合方案分析提示AQ-13非劣效于蒿甲醚-苯芴醇,但意向性分析未达到非劣效标准,需更大样本及非免疫人群研究确认。
主要发现
- 两组均在7天内清除无性体寄生虫,无严重不良事件(2-4级)。
- 共报告453例轻度不良事件(≤1级),蒿甲醚-苯芴醇组214例,AQ-13组239例。
- AQ-13组2例清除后退出、3例失访;对照组2例晚期治疗失败。
关键数值与推荐
- 非劣效界值设为15%,若对照组治愈率高于AQ-13组且差异95%CI上限小于15%则非劣效成立。
- 主要复合终点为第7天无性体寄生虫和发热清除,且第8-42天无相同分子标记的再燃感染(定义为治愈)。
临床怎么用
- AQ-13在符合方案人群中显示与蒿甲醚-苯芴醇相似的治愈率,但意向性分析结果不支持非劣效,暂不能推荐广泛使用。
- 试验中AQ-13未出现治疗失败,但脱落影响结论,临床决策需等待更大规模研究。
局限性
- 样本量小(66例),仅纳入成年男性且来自马里单一地区。
- 意向性分析因AQ-13组5例脱落未满足非劣效标准,结论受脱落影响。
- 未纳入非免疫人群,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chloroquine was used for malaria treatment until resistant Plasmodium falciparum was identified. Because 4-aminoquinolines with modified side chains, such as AQ-13, are active against resistant parasites, we compared AQ-13 against artemether plus lumefantrine for treatment of uncomplicated P falciparum malaria. METHODS: We did a randomised, non-inferiority trial. We screened men (≥18 years) with uncomplicated malaria in Missira (northeast Mali) and Bamako (capital of Mali) for eligibility (≥2000 asexual P falciparum parasites per μL of blood). Eligible participants were randomly assigned to either the artemether plus lumefantrine group or AQ-13 group by permuting blocks of four with a random number generator. Physicians and others caring for the participants were masked, except for participants who received treatment and the research pharmacist who implemented the randomisation and provided treatment. Participants received either 80 mg of oral artemether and 480 mg of oral lumefantrine twice daily for 3 days or 638·50 mg of AQ-13 base (two oral capsules) on days 1 and 2, and 319·25 mg base (one oral capsule) on day 3. Participants were monitored for parasite clearance (50 μL blood samples twice daily at 12 h intervals until two consecutive negative samples were obtained) and interviewed for adverse events (once every day) as inpatients during week 1. During the 5-week outpatient follow-up, participants were examined for adverse events and recurrent infection twice per week. All participants were included in the intention-to-treat analysis and per-protocol analysis, except for those who dropped out in the per-protocol analysis. The composite primary outcome was clearance of asexual parasites and fever by day 7, and absence of recrudescent infection by parasites with the same molecular markers from days 8 to 42 (defined as cure). Non-inferiority was considered established if the proportion of patients who were cured was higher for artemether plus lumefantrine than for AQ-13 and the upper limit of the 95% CI was less than the non-inferiority margin of 15%. This trial is registered at ClinicalTrials.gov, number NCT01614964. FINDINGS: Between Aug 6 and Nov 18, 2013, and between Sept 18 and Nov 20, 2015, 66 Malian men with uncomplicated malaria were enrolled. 33 participants were randomly assigned to each group. There were no serious adverse events (grade 2-4) and asexual parasites were cleared by day 7 in both groups. 453 less-severe adverse events (≤grade 1) were reported: 214 in the combination group and 239 in the AQ-13 group. Two participants withdrew from the AQ-13 group after parasite clearance and three were lost to follow-up. In the artemether plus lumefantrine group, two participants had late treatment failures (same markers as original isolates). On the basis of the per-protocol analysis, the AQ-13 and artemether plus lumefantrine groups had similar proportions cured (28 [100%] of 28 vs 31 [93·9%] of 33; p=0·50) and AQ-13 was not inferior to artemether plus lumefantrine (difference -6·1%, 95% CI -14·7 to 2·4). Proportions cured were also similar between the groups in the intention-to-treat analysis (28 of 33, 84·8% for AQ-13 vs 31 of 33, 93·9% for artemether and lumefantrine; p=0·43) but the upper bound of the 95% CI exceeded the 15% non-inferiority margin (difference 9·1%, 95% CI -5·6 to 23·8). INTERPRETATION: The per-protocol analysis suggested non-inferiority of AQ-13 to artemether plus lumefantrine. By contrast, the intention-to-treat analysis, which included two participants who withdrew and three who were lost to follow-up from the AQ-13 group, did not meet the criterion for non-inferiority of AQ-13, although there were no AQ-13 treatment failures. Studies with more participants (and non-immune participants) are needed to decide whether widespread use of modified 4-aminoquinolones should be recommended. FUNDING: US Food and Drug Administration Orphan Product Development, National Institutes of Health, US Centers for Disease Control and Prevention, Burroughs-Wellcome Fund, US State Department, and WHO.
引用
- Koita OA, Sangaré L, Miller HD, et al. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect Dis. 2017. PMID: 28916443. doi:10.1016/S1473-3099(17)30365-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。